{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:26:25Z","timestamp":1763706385177,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"KERN PHARMA Pharmaceutical"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Corticosteroids are one of the few drugs that have shown a reduction in mortality in coronavirus disease 2019 (COVID-19). In the RECOVERY trial, the use of dexamethasone reduced 28-day mortality compared to standard care in hospitalized patients with suspected or confirmed COVID-19 requiring supplemental oxygen or invasive mechanical ventilation. Evidence has shown that 30% of COVID-19 patients with mild symptoms at presentation will progress to acute respiratory distress syndrome (ARDS), particularly patients in whom laboratory inflammatory biomarkers associated with COVID-19 disease progression are detected. We postulated that dexamethasone treatment in hospitalized patients with COVID-19 pneumonia without additional oxygen requirements and at risk of progressing to severe disease might lead to a decrease in the development of ARDS and thereby reduce death.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods\/design<\/jats:title>\n                <jats:p>This is a multicenter, randomized, controlled, parallel, open-label trial testing dexamethasone in 252 adult patients with COVID-19 pneumonia who do not require supplementary oxygen on admission but are at risk factors for the development of ARDS. Risk for the development of ARDS is defined as levels of lactate dehydrogenase\u2009&gt;\u2009245 U\/L, C-reactive protein\u2009&gt;\u2009100\u00a0mg\/L, and lymphocyte count of\u2009&lt;\u20090.80\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L. Eligible patients will be randomly assigned to receive either dexamethasone or standard of care. Patients in the dexamethasone group will receive a dose of 6\u00a0mg once daily during 7\u00a0days. The primary outcome is a composite of the development of moderate or more severe ARDS and all-cause mortality during the 30-day period following enrolment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>If our hypothesis is correct, the results of this study will provide additional insights into the management and progression of this specific subpopulation of patients with COVID-19 pneumonia without additional oxygen requirements and at risk of progressing to severe disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov NCT04836780. Registered on 8 April 2021 as EARLY-DEX COVID-19.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-022-06722-x","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T19:02:27Z","timestamp":1663268547000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of EARLY administration of DEXamethasone in patients with COVID-19 pneumonia without acute hypoxemic respiratory failure and risk of development of acute respiratory distress syndrome (EARLY-DEX COVID-19): study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1061-0200","authenticated-orcid":false,"given":"Anabel","family":"Franco-Moreno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Soledad","family":"Acedo-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicol\u00e1s Labrador-San","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Hern\u00e1ndez-Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celia","family":"Rodr\u00edguez-Olleros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F\u00e1tima","family":"Ib\u00e1\u00f1ez-Est\u00e9llez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Su\u00e1rez-Sim\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mateo","family":"Balado-Rico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Roc\u00edo","family":"Romero-Paternina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Alonso-Mench\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bel\u00e9n","family":"Escolano-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Piniella-Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ester","family":"Alonso-Monge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Notario-Leo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Bibiano-Guill\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Pe\u00f1a-Lillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando","family":"Antiqueira-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolfo","family":"Romero-Pareja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noem\u00ed","family":"Cabello-Clotet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Estrada-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Troya-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"de Carranza-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismael","family":"Escobar-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nacho","family":"Vallejo-Maroto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Torres-Macho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,15]]},"reference":[{"issue":"10229","key":"6722_CR1","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033\u20134.","journal-title":"Lancet."},{"issue":"1","key":"6722_CR2","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1186\/s13054-020-03240-7","volume":"24","author":"SJ Tzotzos","year":"2020","unstructured":"Tzotzos SJ, Fischer B, Fischer H, Zeitlinger M. Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey. Crit Care. 2020;24(1):516.","journal-title":"Crit Care"},{"issue":"23","key":"6722_CR3","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","volume":"383","author":"DC Fajgenbaum","year":"2020","unstructured":"Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383(23):2255\u201373.","journal-title":"N Engl J Med"},{"issue":"11","key":"6722_CR4","doi-asserted-by":"publisher","first-page":"570993","DOI":"10.3389\/fimmu.2020.570993","volume":"30","author":"L Tang","year":"2020","unstructured":"Tang L, Yin Z, Hu Y, Mei H. Controlling cytokine storm is vital in COVID-19. Front Immunol. 2020;30(11):570993.","journal-title":"Front Immunol"},{"issue":"6","key":"6722_CR5","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jinf.2020.03.037","volume":"80","author":"Q Ye","year":"2020","unstructured":"Ye Q, Wang B, Mao J. The pathogenesis and treatment of the \u2018cytokine storm\u2019 in COVID-19. J Infect. 2020;80(6):607\u201313.","journal-title":"J Infect"},{"issue":"12","key":"6722_CR6","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1007\/s00134-017-4919-5","volume":"43","author":"D Annane","year":"2017","unstructured":"Annane D, Pastores SM, Rochwerg B, Arlt W, Balk RA, Beishuizen A, et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Intensive Care Med. 2017;43(12):1751\u201363.","journal-title":"Intensive Care Med"},{"issue":"4","key":"6722_CR7","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1378\/chest.06-2100","volume":"131","author":"GU Meduri","year":"2007","unstructured":"Meduri GU, Golden E, Freire AX, Taylor E, Zaman M, Carson SJ, et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest. 2007;131(4):954\u201363.","journal-title":"Chest"},{"issue":"3","key":"6722_CR8","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1164\/rccm.200406-808OC","volume":"171","author":"M Confalonieri","year":"2005","unstructured":"Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med. 2005;171(3):242\u20138.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"6722_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/01.CCM.0000194723.78632.62","volume":"34","author":"D Annane","year":"2006","unstructured":"Annane D, S\u00e9bille V, Bellissant E, Ger-Inf-05 Study Group. Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome. Crit Care Med. 2006;34(1):22\u201330.","journal-title":"Crit Care Med."},{"issue":"8","key":"6722_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40560-020-00464-1","volume":"30","author":"Y Zayed","year":"2020","unstructured":"Zayed Y, Barbarawi M, Ismail E, Samji V, Kerbage J, Rizk F, et al. Use of glucocorticoids in patients with acute respiratory distress syndrome: a meta-analysis and trial sequential analysis. J Intensive Care. 2020;30(8):43.","journal-title":"J Intensive Care"},{"key":"6722_CR11","unstructured":"Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Available at: https:\/\/www.idsociety.org\/practice-guideline\/covid-19-guideline-treatment-and-management\/ [Last accessed 10 Sept\u00a02021]."},{"issue":"372","key":"6722_CR12","doi-asserted-by":"publisher","first-page":"n526","DOI":"10.1136\/bmj.n526","volume":"1","author":"F Lamontagne","year":"2021","unstructured":"Lamontagne F, Agoritsas T, Siemieniuk R, Rochwerg B, Bartoszko J, Askie L, et al. A living WHO guideline on drugs to prevent COVID-19. BMJ. 2021;1(372):n526.","journal-title":"BMJ"},{"key":"6722_CR13","unstructured":"Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [Internet]. Bethesda (MD): National Institutes of Health (US); 2021 Apr 21\u20132021 Sep 29. PMID: 34003615. Available at: https:\/\/files.covid19treatmentguidelines.nih.gov\/guidelines\/archive\/covid19treatmentguidelines-09-29-2021.pdf [Last accessed 5 Oct\u00a02021]."},{"issue":"6","key":"6722_CR14","doi-asserted-by":"publisher","first-page":"e440","DOI":"10.1097\/CCM.0000000000004363","volume":"48","author":"W Alhazzani","year":"2020","unstructured":"Alhazzani W, M\u00f8ller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Crit Care Med. 2020;48(6):e440\u201369.","journal-title":"Crit Care Med"},{"issue":"8","key":"6722_CR15","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"P Horby","year":"2021","unstructured":"Recovery Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384(8):693\u2013704.","journal-title":"N Engl J Med."},{"key":"6722_CR16","doi-asserted-by":"crossref","unstructured":"WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA. 2020;324(13):1330\u201341.","DOI":"10.1001\/jama.2020.17023"},{"issue":"47","key":"6722_CR17","doi-asserted-by":"publisher","first-page":"e23315","DOI":"10.1097\/MD.0000000000023315","volume":"99","author":"P Ji","year":"2020","unstructured":"Ji P, Zhu J, Zhong Z, Li H, Pang J, Li B, et al. Association of elevated inflammatory markers and severe COVID-19: a meta-analysis. Medicine (Baltimore). 2020;99(47):e23315.","journal-title":"Medicine (Baltimore)."},{"issue":"1","key":"6722_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40001-020-00432-3","volume":"25","author":"S Ghahramani","year":"2020","unstructured":"Ghahramani S, Tabrizi R, Lankarani KB, Kashani SMA, Rezaei S, Zeidi N, et al. Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: a systematic review and meta-analysis. Eur J Med Res. 2020;25(1):30.","journal-title":"Eur J Med Res."},{"key":"6722_CR19","doi-asserted-by":"crossref","unstructured":"Martha JW, Wibowo A, Pranata R. Prognostic value of elevated lactate dehydrogenase in patients with COVID-19: a systematic review and meta-analysis. Postgrad Med J. 2021:postgradmedj-2020\u2013139542.","DOI":"10.1136\/postgradmedj-2020-139542"},{"key":"6722_CR20","doi-asserted-by":"crossref","unstructured":"Lentner J, Adams T, Knutson V, Zeien S, Abbas H, Moosavi R, et al. C-reactive protein levels associated with COVID-19 outcomes in the United States. J Osteopath Med. 2021;121(12):869\u201373.","DOI":"10.1515\/jom-2021-0103"},{"issue":"1","key":"6722_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12890-021-01422-9","volume":"21","author":"S Wang","year":"2021","unstructured":"Wang S, Sheng Y, Tu J, Zhang L. Association between peripheral lymphocyte count and the mortality risk of COVID-19 inpatients. BMC Pulm Med. 2021;21(1):55.","journal-title":"BMC Pulm Med"},{"key":"6722_CR22","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191\u20134.","journal-title":"JAMA"},{"key":"6722_CR23","unstructured":"Exceptional measures applicable to clinical trials to manage problems arising from the COVID-19 emergency. Available at: https:\/\/www.aemps.gob.es\/informa\/notasinformativas\/medicamentosusohumano-3\/2020-medicamentosusohumano-3\/medidas-excepcionales-aplicables-a-los-ensayos-clinicos-para-gestionar-los-problemas-derivados-de-la-emergencia-por-covid-19\/#notaspie [Last accessed 10 June 2021]."},{"issue":"6","key":"6722_CR24","first-page":"506","volume":"38","author":"AW Chan","year":"2015","unstructured":"Chan AW, Tetzlaff JM, Altman DG, Laupacis A, G\u00f8tzsche PC, Krle A-Jeri\u0107 K, et al. SPIRIT 2013 Statement: defining standard protocol items for clinical trials. Rev Panam Salud Publica. 2015;38(6):506\u201314.","journal-title":"Rev Panam Salud Publica."},{"key":"6722_CR25","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/dexamethasone-epar-product-information_en.pdf [Last accessed 09 Aug\u00a02021]."},{"issue":"23","key":"6722_CR26","first-page":"2526","volume":"307","author":"VM Ranieri","year":"2012","unstructured":"ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526\u201333.","journal-title":"JAMA."},{"issue":"1","key":"6722_CR27","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1186\/s12879-021-06536-3","volume":"21","author":"ZG Dessie","year":"2021","unstructured":"Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis. 2021;21(1):855.","journal-title":"BMC Infect Dis"},{"key":"6722_CR28","unstructured":"https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/clinical-trials\/clinical-trials-regulation [Last accessed 10 Sept\u00a02021]."},{"issue":"11","key":"6722_CR29","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1001\/jama.2020.1585","volume":"323","author":"D Wang","year":"2020","unstructured":"Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan. China JAMA. 2020;323(11):1061\u20139.","journal-title":"China JAMA"},{"key":"6722_CR30","doi-asserted-by":"publisher","unstructured":"Jianfeng Wu, Jianqiang Huang, Guochao Zhu, Yihao Liu, Han Xiao, Qian Zhou, et al. Systemic corticosteroids show no benefit in severe and critical COVID-19 patients in Wuhan, China: a retrospective cohort study. medRxiv 2020.05.11.20097709. https:\/\/doi.org\/10.1101\/2020.05.11.20097709","DOI":"10.1101\/2020.05.11.20097709"},{"issue":"6","key":"6722_CR31","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1080\/10408363.2020.1770685","volume":"57","author":"G Ponti","year":"2020","unstructured":"Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 2020;57(6):389\u201399.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"6722_CR32","first-page":"1","volume":"5","author":"LP Cordeiro","year":"2021","unstructured":"Cordeiro LP, Linhares EONN, Nogueira FGO, Moreira-Silva D, Medeiros-Lima DJM. Perspectives on glucocorticoid treatment for COVID-19: a systematic review. Pharmacol Rep. 2021;5:1\u20138.","journal-title":"Pharmacol Rep"},{"issue":"1","key":"6722_CR33","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1186\/s12879-021-06548-z","volume":"21","author":"J Li","year":"2021","unstructured":"Li J, Liao X, Zhou Y, Wang L, Yang H, Zhang W, et al. Association between glucocorticoids treatment and viral clearance delay in patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):1063.","journal-title":"BMC Infect Dis."},{"key":"6722_CR34","first-page":"1","volume":"13","author":"G El-Saber Batiha","year":"2022","unstructured":"El-Saber Batiha G, Al-Gareeb AI, Saad HM, Al-Kuraishy HM. COVID-19 and corticosteroids: a narrative review. Inflammopharmacology. 2022;13:1\u201317.","journal-title":"Inflammopharmacology"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06722-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06722-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06722-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T19:06:51Z","timestamp":1663268811000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06722-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,15]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["6722"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06722-x","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2022,9,15]]},"assertion":[{"value":"21 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is being carried out in accordance with the recommendations of the institutional Ethics in Human Research Committees. All participants will have given informed consent to one of the study investigators in accordance with the Declaration of Helsinki. Fundaci\u00f3n para la Investigaci\u00f3n e Innovaci\u00f3n Biom\u00e9dica (FIIB) del Hospital Universitario Infanta Leonor y Hospital Universitario del Sureste is the sponsor of EARLY-DEX COVID-19 trial. Ethical approval was obtained by the Ethics Committees for investigation with medicinal products of the Comunidad de Madrid.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study is funded by the pharmaceutical laboratory Kern Pharma, S.L. Dexamethasone will be provided free of charge for this study by Kern Pharma, S.L. The funding body had no input into the study design or in the writing of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"784"}}